Analysts surveyed by FactSet expected, on average, earnings of $1.58 per share on $5.65 billion in revenue. Analysts typically exclude one-time items from their estimates.

Teva closed its $6.8 billion acquisition of drug maker Cephalon Inc. last fall, after the U.S. Federal Trade Commission cleared the deal. Cephalon makes cancer drugs and the sleep disorder drug Provigil, among other products.

Teva said Wednesday its U.S. revenue jumped 32 percent in the quarter due largely to that acquisition and strong branded drug sales. Branded product revenue climbed 68 percent, mainly because Teva included Cephalon products like Provigil, which generated $350 million.

Generic product revenue rose 12 percent to $3 billion, helped by the launch of a generic version of the antipsychotic Zyprexa and an agreement tied to the launch of a generic form of the cholesterol fighter Lipitor.

The addition of Cephalon also contributed to a 26 percent increase in selling and marketing expenses and a rise in research and development costs.

Teva's cost of sales rose 43 percent to $2.79 billion, and the company said exchange rate differences reduced revenue by $29 million.

For the full year, Teva earned $2.76 billion, or $3.09 per share, down from $3.3 billion, or $3.67 per share, a year ago. Revenue rose to $18.31 billion from $16.1 billion a year ago.